SynthesisDigestive diseases and sciences2015
Hepatitis C Infection in the Elderly.
Synthesis in Digestive diseases and sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older.PloS one · 2019Trial
- Hepatitis C Virus Infection in the Elderly in the Era of Direct-Acting Antivirals: Evidence from Clinical Trials and Real Life.Tropical medicine and infectious disease · 2023Review
- Safety and efficacy of directly-acting antiviral therapy for chronic hepatitis C virus in elderly people.Aging medicine (Milton (N.S.W)) · 2021Article
- Liver transplantation and aging.World journal of transplantation · 2020Review
- Anticholinergic Burden and Safety Outcomes in Older Patients with Chronic Hepatitis C: A Retrospective Cohort Study.International journal of environmental research and public health · 2020Observational
- Update on Hepatitis C Epidemiology: Unaware and Untreated Infected Population Could Be the Key to Elimination.SN comprehensive clinical medicine · 2020Review
- Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.Journal of gastroenterology · 2019Article
- Changing trends in complications of chronic hepatitis C.Liver international : official journal of the International Association for the Study of the Liver · 2018Observational
- Efficacy and safety of sofosbuvir and ledipasvir in Japanese patients aged 75 years or over with hepatitis C genotype 1.World journal of hepatology · 2017Article
- Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease.The American journal of gastroenterology · 2017Article
- Article
- Treatment of Hepatitis C Virus Infection in Liver Transplant Recipients.Gastroenterology & hepatology · 2016Article
- Spotlight on grazoprevir-elbasvir once-daily combination and its potential in the treatment of hepatitis C.Drug design, development and therapy · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) infection in the elderly population is a global medical burden and healthcare utilization concern. The majority of patients with hepatitis C in the USA are "baby boomers," who were born between 1945 and 1965. Consistently worldwide, HCV infection in elderly population is overrepresented and poses public health concerns. These individuals have been infected now for over two decades and are presenting with advanced liver disease. Traditionally, the use of pegylated interferon-based therapy has been limited in the elderly because of its adverse effects. The sustained virologic responses have also tended to be lower in the elderly than in younger adults. The emergence of non-interferon-based therapy with direct acting antiviral agents has expanded the pool of patients eligible for treatment. These agents have been found to be effective, tolerable, and safe in the elderly population.
Indexed as
Identifiers
26008618What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.